hypoparathyrodism

  1. Nelson Vergel

    FDA review panel recommends approval of PTH therapy for hypoparathyroidism

    The drug, which was previously approved for osteoporosis treatment in Europe from 2006 to 2013, met the primary endpoints of decreased need for vitamin D and calcium in patients with hypoparathyroidism, as was shown by the manufacturer in their pivotal trial. “A once-a-day injection provided a...
Top